Table 1.
Patient characteristics at baseline
| No RFA (n=3476) | RFA (n=2661) | P value | |
|---|---|---|---|
| Age, years, mean (SD) | 67.1(11.3) | 59.3(10.5) | <0.001 |
| Sex, male, n (%) | 1885(54.2) | 1734(65.2) | <0.001 |
| BMI, mean (SD) | 24.4(3.8) | 24.8(3.3) | <0.001 |
| Smoking, n(%) | 2199(63.3) | 1730(65.0) | 0.003 |
| Alcohol, n(%) | 1460(42.0) | 1104(41.5) | 0.332 |
| Comorbidities, n(%) | |||
| Hypertension | 2039(58.7) | 1262(47.4) | <0.001 |
| Diabetes mellitus | 720(20.7) | 361(13.6) | <0.001 |
| Congestive heart failure | 199(5.7) | 10(0.4) | <0.001 |
| Coronary heart disease | 307(8.8) | 29(1.1) | <0.001 |
| Renal insufficiency | 271(7.8) | 25(0.9) | <0.001 |
| Hypohepatia | 87(2.5) | 14(0.5) | <0.001 |
| Vascular disease | 593(17.1) | 60(0.23) | <0.001 |
| Laboratories | |||
| TBIL, umol/L, mean (SD) | 17.1(9.1) | 15.4(6.0) | <0.001 |
| ALT, IU/L, mean (SD) | 28.4(41.8) | 25.8(19.2) | 0.332 |
| AST, IU/L, mean (SD) | 45.5(66.2) | 35.4(28.8) | <0.001 |
| Creatinine, umol/L, mean (SD) | 85.3(30.2) | 78.3(17.3) | <0.001 |
| PLT, 109/L, mean (SD) | 183.2(65.8) | 187.5(50.6) | <0.001 |
| Hb, g/L, mean (SD) | 132.0(17.2) | 138.3(14.5) | <0.001 |
| Combined medication, n(%) | |||
| Antiplatelet drugs | 1009(29.0) | 676(25.4) | 0.002 |
| PPI | 2166(62.3) | 1971(74.0) | <0.001 |
| Statins | 1902(54.7) | 1187(44.6) | <0.001 |
| Amiodarone | 557(16.0) | 527(19.8) | <0.001 |
| H2-blockers | 1098(31.6) | 843(31.7) | 0.939 |
| ACEI | 877(25.2) | 575(31.6) | 0.001 |
| ARB | 950(27.3) | 643(24.2) | 0.005 |
| β-Blockers | 2338(67.3) | 1739(65.3) | 0.006 |
| CCB | 1110(31.9) | 829(31.1) | 0.515 |
| Diltiazem | 556(16.0) | 392(14.7) | 0.174 |
| Digoxin | 419(12.1) | 240(9.0) | <0.001 |
| CHA2DS2-VASc, Mean(SD) | 2.5(1.5) | 1.9(1.2) | <0.001 |
| HAS-BLED, Mean(SD) | 1.5(0.9) | 1.3(0.9) | <0.001 |
RFA Radiofrequency ablation, SD Standard deviation, BMI Body mass index, TBIL Total bilirubin, ALT Alanine transaminase, AST Aspartate transaminase, PLT Platelet count, Hb Hemoglobin, PPI Proton pump inhibitor, ACEI Angiotensin converting enzyme inhibitor, ARB Angiotensin receptor blockers, CCB Calcium calcium entry blockers